Small Cell Lung Cancer (SCLC)

Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.

A recent study found that giving sinoatrial node radiation therapy during chemoradiotherapy may increase the likelihood of atrial fibrillation in patients with small cell lung cancer and non–small cell lung cancer.

Anne Chiang, MD, PhD, discussed results from a pilot study of biomarkers in tumors treated with ipilimumab and nivolumab in extensive-stage small cell lung cancer.

Charles M. Rudin, MD, PhD, discussed results of the phase 3 SKYSCRAPER-02 trial examining atezolizumab with carboplatin and etoposide with or without tiragolumab in untreated extensive-stage small cell lung cancer.

After approximately 3.5 years of follow-up, patients with treatment-naive extensive-stage small cell lung cancer continued to derive survival benefit from pembrolizumab and etoposide.

Data from the phase 2 UCLA/TRIO-US L-07 trial presented at 2022 WCLC revealed that efficacy with talazoparib plus temozolomide improves upon historical controls in patients with extensive-stage small cell lung cancer.

Response rates with temozolomide plus nivolumab in extensive-stage small cell lung cancer show promise.

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.

The addition of tiragolumab to atezolizumab plus carboplatin and etoposide did not yield improved overall survival or progression-free survival rates in patients with extensive-stage small cell lung cancer.

The phase 3 JUPITER-08 trial assessed toripalimab plus chemotherapy, which was granted an orphan drug designation by the FDA, in patients with extensive-stage small cell lung cancer.

A phase 3 trial of patients with extensive-stage small cell lung cancer who were treated with adebrelimab plus chemotherapy compared with matched placebo met the primary end point of overall survival.

Those with inflamed T cell or YAP1–positive extensive-stage small cell lung cancer were likely to gain an improvement in overall survival following treatment with durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Serplulimab, which has been granted orphan drug designation by the FDA, is being considered as a treatment for patients with small cell lung cancer.

Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.

Treatment with serplulimab yielded a significant improvement in overall survival in combination with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer.

Compared with whole brain radiotherapy alone, the addition of local radiation boost to whole brain radiotherapy improved overall survival and progression-free survival among patients with small cell lung cancer and brain metastases.

A exposure-response analysis indicated that a 3.2mg/m2 dose of lurbinectedin every 3 weeks achieved a favorable risk/benefit profile in patients with small cell lung cancer.

On or after week 5 of treatment with chemotherapy, trilaciclib reduced the need for supportive care therapies in patients with extensive-stage small-cell lung cancer.

Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.

Patients with extensive-stage small cell lung cancer (ES-SCLC) derived overall survival benefit from a combination of durvalumab and chemotherapy.

Hippocampal avoidance–prophylactic cranial irradiation was associated with better cognitive function preservation versus standard prophylactic cranial irradiation for small cell lung cancer.

Two posters on the efficacy of trilaciclib for treating myelosuppression were presented at the Virtual International Society for Pharmacoeconomics and Outcomes Research 2021.

Chemotherapy-induced myelosuppression was reduced when trilaciclib was used before chemotherapy for patients with extensive-stage small cell lung cancer versus placebo.

Data from The Lancet Oncology found that higher-dose radiotherapy of 60 Gy for patients with small cell lung cancer resulted in survival benefit while maintaining the toxicity profile compared with a radiotherapy at a dose of 45 Gy.

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.

Merck, the manufacturer of pembrolizumab, announced that it would be withdrawing the agent’s indication for the treatment of patients with previously treated SCLC.

The approval of trilaciclib was based on results from a pooled analysis of intent-to-treat datasets from 3 studies of patients with extensive-stage small cell lung cancer in which patients received standard chemotherapy plus either trilaciclib or placebo.

Racial and socioeconomic factors were associated with varying levels of survival for patients with limited-stage small cell lung cancer, with improved survival noted among African American and Asian patients compared with White patients.

Liposomal irinotecan as second-line therapy for SCLC is feasible, safe after frontline platinum therapy failure.

Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.